| Nucleic acid hybridization on an electrically reconfigurable network of gold-coated magnetic nanoparticles enables microRNA detection in blood R Tavallaie, J McCarroll, M Le Grand, N Ariotti, W Schuhmann, E Bakker, ... Nature nanotechnology 13 (11), 1066-1071, 2018 | 259 | 2018 |
| ROS-mediated EB1 phosphorylation through Akt/GSK3β pathway: implication in cancer cell response to microtubule-targeting agents M Le Grand, A Rovini, V Bourgarel-Rey, S Honore, S Bastonero, ... Oncotarget 5 (10), 3408, 2014 | 44 | 2014 |
| Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation M Le Grand, A Mukha, J Püschel, E Valli, A Kamili, O Vittorio, ... Theranostics 10 (14), 6411, 2020 | 41 | 2020 |
| Graphene oxide functional nanohybrids with magnetic nanoparticles for improved vectorization of doxorubicin to neuroblastoma cells L Lerra, A Farfalla, B Sanz, G Cirillo, O Vittorio, F Voli, M Le Grand, ... Pharmaceutics 11 (1), 3, 2018 | 37 | 2018 |
| Doxorubicin synergism and resistance reversal in human neuroblastoma BE (2) C cell lines: An in vitro study with dextran-catechin nanohybrids O Vittorio, M Le Grand, SA Makharza, M Curcio, P Tucci, F Iemma, ... European Journal of Pharmaceutics and Biopharmaceutics 122, 176-185, 2018 | 28 | 2018 |
| Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression M Le Grand, R Berges, E Pasquier, MP Montero, L Borge, A Carrier, ... Scientific reports 7 (1), 45136, 2017 | 27 | 2017 |
| Olesoxime favors oligodendrocyte differentiation through a functional interplay between mitochondria and microtubules K Magalon, M Le Grand, B El Waly, M Moulis, R Pruss, T Bordet, M Cayre, ... Neuropharmacology 111, 293-303, 2016 | 26 | 2016 |
| In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor J Ariey‐Bonnet, K Carrasco, M Le Grand, L Hoffer, S Betzi, M Feracci, ... Molecular Oncology 14 (12), 3083-3099, 2020 | 23 | 2020 |
| ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma ER Jackson, RJ Duchatel, DE Staudt, ML Persson, A Mannan, S Yadavilli, ... Cancer research 83 (14), 2421-2437, 2023 | 22 | 2023 |
| Metronomic chemotherapy modulates clonal interactions to prevent drug resistance in non-small cell lung cancer M Bondarenko, M Le Grand, Y Shaked, Z Raviv, G Chapuisat, C Carrère, ... Cancers 13 (9), 2239, 2021 | 20 | 2021 |
| Stathmin levels alter PTPN14 expression and impact neuroblastoma cell migration ST Po’uha, M Le Grand, MB Brandl, AJ Gifford, GJ Goodall, ... British Journal of Cancer 122 (3), 434-444, 2020 | 10 | 2020 |
| Targeting functional activity of AKT has efficacy against aggressive neuroblastoma M Le Grand, K Kimpton, CC Gana, E Valli, JI Fletcher, M Kavallaris ACS Pharmacology & Translational Science 3 (1), 148-160, 2020 | 8 | 2020 |
| Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta-adrenergic receptors in medulloblastoma M Rossi, J Talbot, P Piris, M Le Grand, MP Montero, M Matteudi, ... EBioMedicine 82, 2022 | 5 | 2022 |
| Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms J Ariey-Bonnet, R Berges, MP Montero, B Mouysset, P Piris, K Muller, ... EBioMedicine 95, 2023 | 4 | 2023 |
| Metronomic scheduling: a promising strategy to manage intratumor heterogeneity and control treatment resistance M Carre, M Bondarenko, MP Montero, G Chapuisat, A Benabdallah, ... Cancer Research 75 (15_Supplement), 2572-2572, 2015 | 2 | 2015 |
| BMP2 and BMP7 cooperate with H3. 3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas P Huchedé, S Meyer, C Berthelot, M Hamadou, A Bertrand-Chapel, ... bioRxiv, 2023.08. 09.552628, 2023 | 1 | 2023 |
| Fusion-negative Rhabdomyosarcoma 3D-organoids as an innovative model to predict resistance to cell death inducers C Savary, P Huchedé, L Luciana, A Tourbez, C Deligne, C Picard, T Diot, ... bioRxiv, 2022.09. 06.506756, 2022 | 1 | 2022 |
| Poly-pharmacology of existing drugs: How to crack the code? B Mouysset, M Le Grand, L Camoin, E Pasquier Cancer Letters, 216800, 2024 | | 2024 |
| Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers C Savary, L Luciana, P Huchedé, A Tourbez, C Coquet, M Broustal, ... Cell Reports Medicine 4 (12), 2023 | | 2023 |
| EXTH-36. COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL … E Jackson, R Duchatel, D Staudt, M Persson, A Mannan, S Yadavilli, ... Neuro-Oncology 25 (Supplement_5), v232-v232, 2023 | | 2023 |
Maria KavallarisChildren's Cancer Institute and Australian Centre for NanoMedicine, UNSW SydneyAdresse e-mail validée de ccia.unsw.edu.au
